CAD: response criteria used in clinical trials
| Response level . | Definition . |
|---|---|
| Complete response (CR) | Absence of anemia |
| No signs of hemolysis | |
| Disappearance of clinical symptoms of CAD | |
| No monoclonal serum protein | |
| No signs of clonal lymphoproliferation as assessed by bone marrow histology, immunohistochemistry, and flow cytometry | |
| Partial response (PR) | A stable increase in hemoglobin levels by at least 2.0 g/dL or to the normal range |
| A reduction of serum IgM levels by at least 50% of the initial level or to the normal range | |
| Improvement of clinical symptoms | |
| Transfusion independence | |
| No response | Any outcome not meeting the criteria for CR or PR |
| Response level . | Definition . |
|---|---|
| Complete response (CR) | Absence of anemia |
| No signs of hemolysis | |
| Disappearance of clinical symptoms of CAD | |
| No monoclonal serum protein | |
| No signs of clonal lymphoproliferation as assessed by bone marrow histology, immunohistochemistry, and flow cytometry | |
| Partial response (PR) | A stable increase in hemoglobin levels by at least 2.0 g/dL or to the normal range |
| A reduction of serum IgM levels by at least 50% of the initial level or to the normal range | |
| Improvement of clinical symptoms | |
| Transfusion independence | |
| No response | Any outcome not meeting the criteria for CR or PR |